Barclays
VTVT icon

Barclays’s vTv Therapeutics VTVT Stock Holding History

Barclays’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36
Closed -$1.43K – 5666
2026
Q1 		$1.43K Buy
+36
New +$1.31K ﹤0.01% 4882
2021
Q4 		– Sell
-38
Closed -$2K – 4778
2021
Q3 		$2K Sell
38
-43
-53% -$3.24K ﹤0.01% 4679
2021
Q2 		$7K Sell
81
-167
-67% -$16.9K ﹤0.01% 4718
2021
Q1 		$28K Buy
248
+159
+179% +$15.6K ﹤0.01% 4311
2020
Q4 		$7K Sell
89
-27
-23% -$2.07K ﹤0.01% 4774
2020
Q3 		$9K Sell
116
-15
-11% -$1.32K ﹤0.01% 5029
2020
Q2 		$12K Buy
131
+90
+220% +$8.89K ﹤0.01% 5302
2020
Q1 		$3K Sell
41
-3,148
-99% -$303K ﹤0.01% 5998
2019
Q4 		$217K Buy
+3,189
New +$194K ﹤0.01% 4975
2019
Q3 		– Sell
-116
Closed -$7K – 7165
2019
Q2 		$7K Sell
116
-584
-83% -$35.1K ﹤0.01% 6638
2019
Q1 		$48K Hold
700
– – ﹤0.01% 5910
2018
Q4 		$74K Buy
700
+550
+367% +$50.9K ﹤0.01% 5246
2018
Q3 		$5K Sell
150
-223
-60% -$10.5K ﹤0.01% 6799
2018
Q2 		$23K Buy
373
+321
+617% +$23.7K ﹤0.01% 6111
2018
Q1 		$8K Hold
52
– – ﹤0.01% 6712
2017
Q4 		$13K Buy
52
+40
+333% +$8.97K ﹤0.01% 6459
2017
Q3 		$3K Sell
12
-11
-48% -$2.19K ﹤0.01% 6612
2017
Q2 		$5K Buy
23
+19
+475% +$3.96K ﹤0.01% 6252
2017
Q1 		$1K Sell
4
-8
-67% -$1.82K ﹤0.01% 6642
2016
Q4 		$2K Buy
12
+11
+1,100% +$2.53K ﹤0.01% 6380
2016
Q3 		$0 Buy
+1
New +$241 ﹤0.01% 6816

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's VTVT Position: Q2 2026 in Review

Barclays sold out of vTv Therapeutics (VTVT) in Q2 2026, closing a stake of 36 shares — an estimated $1.43K sold.

Barclays first reported a position in VTVT in Q3 2016 and held it in 21 quarters. The position peaked at $217K in Q4 2019. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Barclays reported no remaining vTv Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Barclays sold 36 vTv Therapeutics shares in Q2 2026, an estimated $1.43K.
  • Barclays first reported a position in vTv Therapeutics in Q3 2016 and held it in 21 quarters.
  • Barclays's vTv Therapeutics position peaked at $217K in Q4 2019.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.